Tumors are one of the diseases that seriously threaten human health, and it is also a big mountain that the medical community is still conquering. In recent years, an innovative method of cancer diagnosis and treatment, pan-tumor disease diagnosis and treatment, has gradually opened up a new pattern of tumor diagnosis and treatment. The reporter learned that at the fourth China International Import Expo, Roche Diagnostics launched the "pan-tumor disease management overall solution", which comprehensively empowered pan-tumor disease management by providing perfect and innovative pathological diagnosis products and services, and provided a solid boost for the diagnosis and treatment of pan-tumor diseases in China.
Group photo of guests at the scene.
To achieve "common treatment of different diseases", accurate pathological diagnosis is the key
Pan-tumor diagnosis and treatment is a diagnosis and treatment concept for different tumors and the same pathological molecular phenotype, which is also often referred to as "treatment of different diseases". This innovative approach to diagnosis and treatment brings new treatment options to oncology patients. At this stage, pan-tumor diagnosis and treatment has entered the clinical practice stage, including pd-1/pd-l1 inhibitor immunotherapy and broad-spectrum targeted diagnosis and treatment. Accurate pathological diagnosis is the key to achieving the goal of "treating different diseases and treating patients with pan-oncology diseases" and bringing treatment benefits.
PD-L1 testing has important guiding value for tumor immunotherapy decision-making. The evaluation of pd-l1 expression in tumor tissues by pd-l1 standard detection system can be used to guide the treatment decision of pd-1 and/or pd-l1 monoclonal antibody drugs, and the high expression of pd-l1 is positively correlated with the efficacy of immunotherapy, which is also of important clinical reference value.
"Taking Roche Diagnostics ventana pd-l1 (sp263) companion diagnostics as an example, the companion diagnostic standard detection system has been supported by evidence in a number of clinical studies of different pd-1/pd-l1 inhibitors, and a total of 5 pd-1/pd-l1 immunosuppressant drugs have been approved in the world for the detection of pd-l1 expression in lung cancer and urothelial carcinoma, which can provide accurate diagnosis and treatment support for patients with different tumor types through the same target." Professor Tang Feng of the Department of Pathology of Huashan Hospital affiliated to Fudan University said, "In addition to the detection of pd-l1, for immunotherapy, with the gradual deepening of clinical research, the diagnosis of mismatch repair (mmr) functional defects in a variety of tumor-related immunotherapy has become increasingly prominent. MMR defects are most common in colorectal cancer, endometrial cancer, and other high-incidence tumor types include stomach cancer, small bowel cancer, cervical cancer, and neuroendocrine cancer. ”
In August 2021, the FDA approved the Roche Diagnostics ventana mmr rxdx panel test combination as a relevant immunotherapy companion diagnosis, which can support clinical "targeted" immunotherapy regimen decisions in patients with recurrent or advanced solid tumors of DMMR.
Professor Tang Feng, Department of Pathology, Huashan Hospital, Fudan University.
In the field of broad-spectrum targeted diagnosis and treatment, promyosin receptor kinase (trk) inhibitors and ntrk (neurotrophic tyrosine receptor tyrosine kinase) gene fusion detection have become successful examples of "heterogeneous treatment". At present, two internationally approved clinical trials of trk inhibitors involve solid tumor types including lung cancer, breast cancer, colorectal cancer, thyroid cancer, and melanoma.
Professor Sheng Weiqi of the Department of Pathology of Fudan University Affiliated Cancer Hospital said: "The diagnosis and treatment management of the same molecular event in different tumor types is a further expansion of the concept of precision medicine in the practice of clinical pathology. Of course, this concept is still developed within the framework of specific pathological morphological types and molecular typing, such as the diagnosis of dmmmr/msi-h solid tumor or ntrk fusion solid tumor, first of all, within the framework of solid tumor, and then consider the incidence of dmmr/msi-h in different tumor types or the incidence of ntrk fusion, molecular pathological characteristics and other differences to discuss the application in practice, can not be generalized. When it comes to the diagnosis of a specific case, a comprehensive assessment based on the diagnosis results of histological type and other molecular target markers is required. ”
Professor Sheng Weiqi, Department of Pathology, Fudan University Affiliated Cancer Hospital.
Digitalization empowers pan-tumor disease management, making "different diseases and the same treatment" more accurate
As an important breakthrough in the field of cancer diagnosis and treatment, pan-tumor disease management needs to further improve the degree of standardization and standardization of pathological diagnosis, especially diagnosis and treatment-related concomitant diagnosis. At the same time, with the advent of the era of smart medical treatment, pathological diagnosis technology will also develop in the direction of intelligence and digitalization, providing accurate support for pan-tumor disease management.
In order to better meet the clinical needs, roche diagnostics, relying on the resource advantages and innovative strength in the field of pathology diagnosis, integrates complete iHC detection products, automated detection platforms and advanced digital pathology analysis software, and grandly launches the overall solution of pan-tumor disease management in the "first" stage of the Expo, including pd-1/pd-l1 inhibitor immunotherapy and broad-spectrum targeted diagnosis and treatment of blockbuster products: ventana pd-l1 (sp263) and ventana PD-L1 (SP142) companion diagnostics, ventana mmr Rxdx panel detection combination, pan-trk (EPR17341) antibody reagent, can be run on the benchmark ultra automatic immunohistochemical staining platform, providing pathologists with efficient and accurate test results.
In terms of digital pathology, Roche Diagnostics has also brought innovative products: ventana dp 200 digital pathology slide scanner and digital pathology image analysis software upath, which was launched at the beginning of this year, equipped with specific detection and analysis algorithms, which can not only help pathologists complete objective and repeatable analysis of slice images more quickly and with high quality, create a laboratory intelligent management platform, but also promote the "seamless docking" of pathology and clinical practice, develop the best treatment strategy for patients, and provide remote consultation, Pathology education and training, third-party pathology diagnostic services and other application areas have brought transformative impacts, leading the new trend of digital pathology development.
Written by: Nandu reporter Zeng Wenqiong
Intern: Xu Ziqing